Eli Lilly Picks Netherlands for New $3 Billion Manufacturing Facility

By Adriano Marchese

 

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines.

The pharmaceutical company said Monday that the new facility will be built in Katwijk in the Leiden Bio Science Park.

The facility will house advanced manufacturing technologies to meet the growing portfolio of oral medicines in Eli Lilly's cardiometabolic health, neuroscience, oncology and immunology segments.

The new site will also be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist which treats type 2 diabetes and obesity.

Eli Lilly already has a large manufacturing presence in Europe with four existing sites across France, Ireland, Italy and Spain, it said. The company also said it plans to expand its existing manufacturing plants in Puerto Rico, and build sites in the U.S. in Texas and Virginia, with two more to be announced shortly.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

November 03, 2025 09:01 ET (14:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center